Glyn Lewis

This study performs a trans-ancestry GWAS of SSRI response in depression, finding suggestive associations and enrichment in serotonergic pathways but no genome-wide significant variants.

This paper identifies 58 genome-wide significant loci for major anxiety disorders using a large meta-analysis and highlights GABAergic signaling as a potential mechanism.

This study examines the association between CYP2C19 and CYP2D6 metabolic phenotypes and antidepressant response using genotype imputation across 13 studies, finding no significant associations after correction for multiple testing.

This paper develops a transcriptome-based polygenic risk score (T-PRS) linking depression-related cortical gene expression changes to brain morphology and symptom severity in MDD.

This paper shows that GWAS using minimal phenotyping for depression identifies non-specific genetic factors shared with other psychiatric conditions, not specific to major depressive disorder.

This study investigates whether genetic variation in the Major Histocompatibility Complex (MHC) is associated with depression risk, finding no significant associations at a conservative threshold.

This paper conducts a meta-analysis showing that CYP2C19 poor metabolizers have better antidepressant efficacy but similar side effects compared to extensive metabolizers.

This study identifies two SNPs associated with antidepressant response in GENDEP and STAR*D studies but finds limited replication in independent cohorts.

This study investigates whether polygenic risk scores (PRS) can predict antidepressant response in MDD, finding no significant predictive effect.